

**Psychedelics & Cutting-Edge Therapies
The Ethics & Clinical Implications
Of Treatment & Referrals**

Advanced Topics in Law & Ethics

Taught by Debra Manchester, LCSW

Saturday November 4, 2023

SYLLABUS

| EDUCATIONAL GOALS & LEARNING OBJECTIVES

Educational Goals:

The past several years have brought significant developments in the effective treatment of depression and anxiety disorders. The goals of this course are twofold: first, to summarize current theories and research so that clinicians can incorporate them into their current practice or be able to make appropriate referrals; second, to outline the legal and clinical issues related to these newer forms of treatment.

Learning Objectives:

Upon completion of this course, the participants will be able:

1. To explain the newest theories about depression and contrast with the monoamine theory of depression
2. To explain how precision psychiatry integrates four new sources of information about the client in order to tailor treatment models to the individual
3. To specify which of their clients might benefit from referrals to cutting edge treatments and where they are available and legal
4. To assess and evaluate good candidates for ketamine assisted psychotherapy
5. To explain the California laws around ketamine and the ethical guidelines in order to protect clients adequately

| COURSE OUTLINE

1. NEW THEORIES OF DEPRESSION
 - a. The monoamine theory
 - b. Research on the effectiveness of traditional anti-depressants
 - c. New research from neuroscience and genetics

2. COMPLEXITY SCIENCE & PRECISION PSYCHIATRY
 - a. History and pioneers of complexity science and mental health
 - b. The precision medicine movement
 - c. The identification of biotypes and implications for treatment
 - d. Referrals to cutting edge treatments

3. KETAMINE AND ITS USE IN PSYCHOTHERAPY
 - a. The history of ketamine and its legal use
 - b. The different forms of ketamine and their ethical use
 - c. Appropriate candidates for ketamine assisted psychotherapy
 - d. Risk factors or inappropriate referrals

4. THE ETHICAL & LEGAL GUIDELINES FOR KAP & OTHER REFERRALS
 - a. Current laws around psychedelics in California
 - b. Appropriate consent to treatment
 - c. Appropriate training, consultation and referrals

| COURSE TIMELINE

9:00am-9:15am: Overview of course and old models of depression

9:15am-10:00am: Research on effectiveness of traditional medications

10am-10:30am: Complexity science and precision psychiatry

10:30-10:40: Break

10:40am-11:50am: Ketamine & its use in psychotherapy

12pm-12:10PM: Wrap-up/questions/discussion

| COURSE REFERENCES

New Laws This Year

Modernizing conservatorship law to better help & protect Californians most in need of care. (2023, October 10). California Governor. <https://www.gov.ca.gov/2023/10/10/modernizing-conservatorship-law-sb43/>

Opting Out of Medicare. (2023, September/October). *The Therapist*, 44. CAMFT.

What Causes Depression and How Effective Are Anti-Depressants?

Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*, 391(10128), 1357–1366. [https://doi.org/10.1016/s0140-6736\(17\)32802-7](https://doi.org/10.1016/s0140-6736(17)32802-7)

Kandel, E. R. (1998). A New Intellectual Framework for Psychiatry. *American Journal of Psychiatry*, 155(4), 457–469. <https://doi.org/10.1176/ajp.155.4.457>

Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2022). The serotonin theory of depression: a systematic umbrella review of the evidence. *Molecular Psychiatry*, 1–14. <https://doi.org/10.1038/s41380-022-01661-0>

NIMH» *Questions and Answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study — All Medication Levels.* (n.d.). [www.nimh.nih.gov](https://www.nimh.nih.gov/funding/clinical-research/practical/stard/allmedicationlevels). <https://www.nimh.nih.gov/funding/clinical-research/practical/stard/allmedicationlevels>

Papakostas, G. I., & Fava, M. (2009). Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. *European Neuropsychopharmacology*, 19(1), 34–40. <https://doi.org/10.1016/j.euroneuro.2008.08.009>

Thompson, J., & Quanta Magazine moderates comments to facilitate an informed, substantive. (2023, June 21). *The cause of depression is probably not what you think.* Quanta Magazine. <https://www.quantamagazine.org/the-cause-of-depression-is-probably-not-what-you-think-20230126/>

Ross, D. A., & Novick, A. M. (2019). Beyond Broca's area. *Revista de Medicina*, 98(4), 238–240. <https://doi.org/10.11606/issn.1679-9836.v98i4p238-240>

Sankar, A., Melin, A., Lorenzetti, V., Horton, P., Costafreda, S. G., & Fu, C. H. Y. (2018). A systematic review and meta-analysis of the neural correlates of psychological therapies in major depression. *Psychiatry Research: Neuroimaging*, 279, 31–39. <https://doi.org/10.1016/j.psychres.2018.07.002>

Impact of Trauma

Nemeroff, Charles B. (2016). Paradise Lost: The Neurobiological and Clinical Consequences of Child Abuse and Neglect. *Neuron*, 89(5), 892–909.

<https://doi.org/10.1016/j.neuron.2016.01.019>

Centers for Disease Control and Prevention. (2020, September 8). Adverse childhood experiences (ACES). www.cdc.gov; Centers for Disease Control and Prevention.

<https://www.cdc.gov/violenceprevention/aces/index.html>

Complexity Science and Precision Psychiatry

Williams, L. M., Hack, L. M., & American Psychiatric Association Publishing. (2022). *Precision psychiatry : using neuroscience insights to inform personally tailored, measurement-based care*. American Psychiatric Association Publishing.

Williams, L. M. (2022). Special Report: Precision Psychiatry—Are We Getting Closer? *Psychiatric News*, 57(9). <https://doi.org/10.1176/appi.pn.2022.09.9.23>

Using Neuroscience Insights to Inform Personally Tailored-Based Care - Speaker Dr. Leanne Williams. (n.d.). www.youtube.com. Retrieved October 31, 2023, from

<https://www.youtube.com/watch?v=ujH2EIF6UA8>

Pharmacogenomics

Alfredo Carlo Altamura, Paolo Brambilla, & Springerlink (Online Service. (2019). *Clinical Cases in Psychiatry: Integrating Translational Neuroscience Approaches*. Springer International Publishing.

Girn, M., Rosas, F. E., Daws, R. E., Gallen, C. L., Gazzaley, A., & Carhart-Harris, R. L. (2023). A complex systems perspective on psychedelic brain action. *Trends in Cognitive Sciences*, 27(5), 433–445. <https://doi.org/10.1016/j.tics.2023.01.003>

Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., Li, J., Brown, K., Gilbert, A., Burns, L., Jablonski, M. R., & Dechairo, B. (2019). Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. *Journal of Psychiatric Research*, 111, 59–67. <https://doi.org/10.1016/j.jpsychires.2019.01.003>

Kleine Schaars, K., & van Westrhenen, R. (2023). Pharmacogenomics and the management of mood disorders-a review. *Journal of Personalized Medicine*, 13(7), 1183.

<https://doi.org/10.3390/jpm13071183>

Accelerated TMS

Brandes, R. (2022, December 22). FDA clears “SAINT”: New magnet therapy for depression. *Nice News*. <https://nicenews.com/health-and-wellness/fda-clears-saint-magnet-therapy/>

TMS, Saint TMS, and Accelerated TMS. (n.d.). NeuroStim TMS | Leading TMS Provider. Retrieved October 31, 2023, from <https://neurostimtms.com/tms-saint-tms-and-accelerated-tms/>

Psychedelics in Psychotherapy

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2020). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. *JAMA Psychiatry*, 78(5), 481–489. <https://doi.org/10.1001/jamapsychiatry.2020.3285>

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of Psychopharmacology*, 30(12), 1181–1197. <https://doi.org/10.1177/0269881116675513>

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology*, 187(3), 268–283. <https://doi.org/10.1007/s00213-006-0457-5>

Ketamine and Ketamine Assisted Therapy

Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. *Biological Psychiatry*, 47(4), 351–354. [https://doi.org/10.1016/s0006-3223\(99\)00230-9](https://doi.org/10.1016/s0006-3223(99)00230-9)

Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. *Journal of Psychoactive Drugs*, 51(2), 189–198. <https://doi.org/10.1080/02791072.2019.1587556>

Gilbert, D. (2023, May 10). This doctor prescribed ketamine from his home. DEA shut it down. *Washington Post*. <https://www.washingtonpost.com/business/2023/05/10/ketamine-telehealth-doctor/>

Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D. S., & Mathew, S. J. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. *American Journal of Psychiatry*, 170(10), 1134–1142. <https://doi.org/10.1176/appi.ajp.2013.13030392>

Wolfson, P., Hartelius, G., & Multidisciplinary Association For Psychedelic Studies. (2016). *The ketamine papers : science, therapy, and transformation*. Multidisciplinary Association for Psychedelic Studies.

Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006). A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression. *Archives of General Psychiatry*, 63(8), 856–864. <https://doi.org/10.1001/archpsyc.63.8.856>